administration of Cimzia

Phase 3Small molecule

UUniversity Hospital, Ghent

administration of Cimzia is one of 204 small molecule programs targeting Nasal polyposis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

203

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasal PolyposisActive, not recruiting

Cerebral PalsyActive, not recruiting

Liver TransplantActive, not recruiting

Acute MyocarditisActive, not recruiting

Colorectal CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Systemic SclerosisActive, not recruiting

AsthmaActive, not recruiting

Nasal PolyposisPhase 2

Active, not recruiting

Cerebral PalsyPhase 2

Active, not recruiting

Liver TransplantPhase 1

Active, not recruiting

Acute MyocarditisPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

administration of Cimzia

UUniversity Hospital, Ghent

Phase 3

1 2

Veramyst

GSK

Preclinical

46 3

Xolair

Roche

Preclinical

25 4

Singulair

AstraZeneca

Preclinical

17 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Asmanex

Novartis

Preclinical

5 7

Celexa

AbbVie

Preclinical

1 8

Arcoxia

Paracetamol

1 10

Blood Withdrawn

Emergent BioSolutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Acute Myocarditis

NCT06522100

Clinical

Trials by Indication[1]

Cerebral Palsy2 trials

Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00221611·80 enrolled

Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00426595·14 enrolled

Rheumatoid Arthritis1 trial

Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis

Completed·UUniversity Hospital, Ghent·Phase 3·NCT01590966·41 enrolled

Nasal polyposis1 trial

Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00480298·48 enrolled

Postoperative Pain Relief1 trial

Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00333346·200 enrolled

Systemic Sclerosis1 trial

A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00379431·9 enrolled

7 more indications

Asthma1 trial

Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00557700·15 enrolled

Fontan1 trial

Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00263406·40 enrolled

Acute1 trial

Acute Haemodynamic Impact of an IV Glucose-injection

Withdrawn·UUniversity Hospital, Ghent·Phase 2·NCT00426114

Acute Myocarditis1 trial

Corticoid Therapy in Acute Myocarditis

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06522100·420 enrolled

Glycopyrrolate1 trial

Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00315536·63 enrolled

Colorectal Cancer1 trial

High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00286000·106 enrolled

Liver Transplant1 trial

Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.

Completed·UUniversity Hospital, Ghent·Phase 1·NCT01290172·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for administration of Cimzia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — administration of Cimzia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for administration of Cimzia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Ghent company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Ghent

administration of Cimzia

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Cerebral Palsy2 trials

Rheumatoid Arthritis1 trial

Nasal polyposis1 trial

Postoperative Pain Relief1 trial

Systemic Sclerosis1 trial

Asthma1 trial

Fontan1 trial

Acute1 trial

Acute Myocarditis1 trial

Glycopyrrolate1 trial

Colorectal Cancer1 trial

Liver Transplant1 trial

References

Drug Info

Quick Facts

Related News